ArticleCancer management and research2026
Development and External Validation of a Preoperative Nomogram for Predicting Axillary Lymph Node Metastasis in Breast Cancer Using Routine Ultrasound and Core Needle Biopsy Variables.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate preoperative assessment of axillary lymph node metastasis (ALNM) is essential for individualized axillary management in breast cancer, yet imaging-based evaluation alone remains imperfect. We aimed to develop and externally validate a practical nomogram based on routinely available preoperative ultrasound and core needle biopsy (CNB) variables. Methods: This retrospective, two-center cohort study included 295 women with pathologically confirmed primary breast cancer who underwent breast surgery with axillary nodal staging between January 2021 and January 2025. The training cohort included 182 patients from the Changji Branch, and the external validation cohort included 113 patients from the First Affiliated Hospital of Xinjiang Medical University. Candidate predictors were evaluated using univariable analysis, LASSO regression, and multivariable logistic regression. Model discrimination, calibration, and clinical utility were assessed using receiver operating characteristic analysis, calibration analysis, and decision curve analysis. Results: ALNM was confirmed in 88 of 182 patients (48.4%) in the training cohort and 50 of 113 patients (44.2%) in the external validation cohort. The final nomogram included ultrasound-reported calcifications, tumor size, histological grade, CNB-derived lymphovascular invasion, and HER2 status. The model showed good discrimination, with an AUC of 0.858 (95% CI 0.805-0.911) in the training cohort and 0.854 (95% CI 0.779-0.929) in the external validation cohort. Calibration and decision curve analyses supported acceptable model performance and potential clinical utility in both cohorts. Conclusion : We developed and externally validated an interpretable preoperative nomogram using routinely obtainable ultrasound and CNB variables for individualized estimation of ALNM risk in breast cancer. The model may support preoperative risk stratification and axillary management planning, although prospective multicenter validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.